A completed biosciences spin-off, and a forward multiple that looks cheap against the peer group make this one of the more interesting setups in healthcare right now.
Sep 22, 2026
•
8 min read
Three approved medicines, a near-term Phase 3 readout, and an FDA decision eight days away make this one of the busiest catalyst windows in biotech right now.
Sep 19, 2026
9 min read
Leadership consolidation aimed at driving out costs, plus a consensus pointing to an earnings recovery, make this one worth understanding before the next print.
Sep 17, 2026
The founding-era operator is back, comps have flipped positive for six straight quarters, and a $700 million buyback is starting in the back half of this year.
Sep 15, 2026
A massive Q2 earnings beat, and a forward earnings multiple below the peer group average make this 3M carveout worth understanding before the next catalyst hits.
Sep 12, 2026
7 min read
This homebuilder is trading below book value just as a shifting rate cycle could give the housing market its next catalyst.
Sep 10, 2026
A clean Phase 3 win in a condition with zero approved treatments, and a freshly loaded balance sheet put this biotech in a genuinely interesting position.
Sep 8, 2026
The billionaire crowd just piled into this power stock while it was still down a third from its highs. That’s not the kind of thing that happens by accident.
Sep 5, 2026
The market keeps hammering this name over weak sales. But its balance sheet looks better by the day, and Wednesday’s bounce could be a sign the tide is turning.
Sep 3, 2026
A biotech just delivered the first successful late-stage trial ever run in its category, and got punished for it. This gap won’t last.
Sep 1, 2026
A company built on sleep medicine just landed a cancer approval that could redraw its growth story, with a valuation that still hasn’t caught up to what the pipeline is worth.
Aug 29, 2026
A diversified wealth platform is growing revenue in double digits, and buying back stock hand over fist, yet trades at a fraction of what comparable US financials command.
Aug 27, 2026
After a brutal reset year, adjusted earnings are forecast to jump in tomorrow’s print, driven by delicious growth, while the stock has run 33% this year.
Aug 25, 2026
A major competitor collapsed, leaving hundreds of valuable locations behind. This beaten-down retailer could be perfectly positioned to take them.
Aug 22, 2026
Organic sales just hit their fastest pace in years, free cash flow margins expanded sharply, and the two fastest-growing brands in the portfolio have barely scratched the surface of their international potential.
Aug 20, 2026
This title insurer reported its strongest commercial revenue in years, and still trades at 10 times forward earnings, while the full residential recovery sits in front of it.
Aug 18, 2026
A landscape supply distributor with 90-plus acquisitions and a CEO who just wrote an $816K personal check is trading near a 52-week low while analysts see 30% upside. See if it makes sense.
Aug 15, 2026
A SaaS company beat Q2 by 30%, raised guidance, and just achieved GAAP profitability while growing its employee experience platform at the fastest rate in the business. Find out if it belongs in your portfolio.
Aug 13, 2026
A medical imaging leader beat Q2 earnings by 9%, hit a record $23.9 billion backlog, and is reviewing its weakest segment for a potential sale.
Aug 11, 2026
The company that built the digital infrastructure of an entire economy trades at a massive discount to peers, reports Q2 Monday, and yields nearly 8%. Find out if the setup is worth the country risk.
Aug 8, 2026
The company that builds the boards inside AI switches and defense radar systems reports Q2 results tomorrow. Four consecutive earnings beats behind it and 55% growth expected. See if it belongs in your portfolio.
Aug 4, 2026
An aerospace alloys supplier has beaten estimates for four quarters in a row, has Q2 earnings next week with 40% expected growth. Find out if the setup is worth owning.
Aug 1, 2026
A water company’s stock fell roughly 44% from its high after a surprise guidance cut and CFO exit, then bounced nearly 5% on Q2 earnings day. Find out if the recovery is real or the setup still needs more time.
Jul 28, 2026
This AI networking hardware company has posted four consecutive earnings beats. Find out if it belongs in your portfolio.
Jul 25, 2026
A rejected $53 billion takeover bid, Q2 earnings on July 28, and one analyst arguing the real value is closer to $70 per share. See if the setup justifies a position.
Jul 21, 2026
